Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Short term Debt (2016 - 2025)

Surgery Partners (SGRY) has disclosed Short term Debt for 12 consecutive years, with $99.3 million as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 2.07% to $99.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.3 million through Dec 2025, down 2.07% year-over-year, with the annual reading at $99.3 million for FY2025, 2.07% down from the prior year.
  • Short term Debt hit $99.3 million in Q4 2025 for Surgery Partners, down from $103.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $116.9 million in Q3 2022 to a low of $60.4 million in Q4 2021.
  • Historically, Short term Debt has averaged $80.8 million across 5 years, with a median of $71.4 million in 2021.
  • Biggest five-year swings in Short term Debt: surged 92.27% in 2022 and later crashed 46.88% in 2023.
  • Year by year, Short term Debt stood at $60.4 million in 2021, then grew by 3.97% to $62.8 million in 2022, then rose by 16.72% to $73.3 million in 2023, then surged by 38.34% to $101.4 million in 2024, then fell by 2.07% to $99.3 million in 2025.
  • Business Quant data shows Short term Debt for SGRY at $99.3 million in Q4 2025, $103.0 million in Q3 2025, and $110.0 million in Q2 2025.